Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials-Reference-Cited by-同舟云学术

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

Published:2015-06 Issue:1 Volume:62 Page:25-30
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Alqahtani Saleh A.¹,Afdhal Nezam²,Zeuzem Stefan³,Gordon Stuart C.⁴,Mangia Alessandra⁵,Kwo Paul⁶,Fried Michael⁷,Yang Jenny C.⁸,Ding Xiao⁸,Pang Phillip S.⁸,McHutchison John G.⁸,Pound David⁹,Reddy K. Rajender¹⁰,Marcellin Patrick¹¹,Kowdley Kris V.¹²,Sulkowski Mark¹

Affiliation:

1. Department of MedicineJohns Hopkins HospitalBaltimore MD

2. HepatologyBeth Israel Deaconess Medical CenterBoston MA

3. Department of MedicineJohann Wolfgang Goethe UniversityFrankfurt Germany

4. GastroenterologyHenry Ford Health SystemDetroit MI

5. Department of HepatologyCasa Sollievo della Sofferenza HospitalSan Giovanni Rotondo Italy

6. Gastroenterology‐HepatologyIndiana University School of MedicineIndianapolis IN

7. Liver CenterUniversity of North Carolina Health CareChapel Hill NC

8. Liver DiseasesGilead Sciences, IncFoster City CA

9. Indianapolis Gastroenterology Research FoundationIndianapolis IN

10. Division of GastroenterologyHospital of the University of PennsylvaniaPhiladelphia PA

11. Department of HepatologyCentre Hospitalier Universitaire BeaujonClichy‐sous‐Bois France

12. Liver Care Network and Organ Care ResearchSwedish Medical CenterSeattle WA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27890

Reference18 articles.

1. American Association for the Study of Liver Diseases & Infectious Diseases Society of America.Recommendations for testing managing and treating hepatitis C.2014. Available at:http://www.hcvguidelines.org/. Accessed on February 28 2015.

2. Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects

3. Ribavirin as Therapy for Chronic Hepatitis C

4. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety considerations in the management of hepatitis C and HIV co-infection;Expert Opinion on Drug Safety;2023-04-27

2. Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil;Revista do Instituto de Medicina Tropical de São Paulo;2023

3. Outcome of Treatment for Hepatitis C Infection in Hemodialysis Patients with Direct-Acting Second-Generation anti-HCV Drugs at Azzawiyah Kidney Hospital, Libya;Libyan Journal of Medical Sciences;2022-04

4. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019;Scientific Reports;2022-01-27

5. Willingness to participate in research among black patients with liver disease: A national cross‐sectional study;Journal of Viral Hepatitis;2021-04-26